However, TAMs and MDSCs are the main target cells of TP‐16, and the PGE2‐EP4 signaling pathway facilitates cancer‐promoting immunoreaction in other immune cells, such as suppression of natural killer cell activity and induction of Treg cell development (O'Callaghan & Houston, 2015). Here, CDKN2A is linked to cancer.